SRR613807
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.397
- ANGIOGENESIS+0.341
- APICAL_SURFACE+0.334
- CHOLESTEROL_HOMEOSTASIS+0.321
- IL2_STAT5_SIGNALING+0.309
- INFLAMMATORY_RESPONSE+0.309
- INTERFERON_GAMMA_RESPONSE+0.309
- TNFA_SIGNALING_VIA_NFKB+0.295
- APICAL_JUNCTION+0.273
- ALLOGRAFT_REJECTION+0.250
Top 10 suppressed
- E2F_TARGETS-0.446
- MYC_TARGETS_V1-0.426
- MYC_TARGETS_V2-0.420
- G2M_CHECKPOINT-0.391
- DNA_REPAIR-0.386
- NOTCH_SIGNALING-0.294
- UNFOLDED_PROTEIN_RESPONSE-0.283
- OXIDATIVE_PHOSPHORYLATION-0.241
- HEDGEHOG_SIGNALING-0.209
- UV_RESPONSE_DN-0.133
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR612407 | GTEX | — | 0.882 |
| 2 | SRR1340133 | GTEX | — | 0.876 |
| 3 | SRR1330498 | GTEX | — | 0.856 |
| 4 | TCGA-38-4626-01A-01R-1206-07 | — | cohortMD2 | 0.855 |
| 5 | ERR2598319 | fetal | fetal | 0.842 |
| 6 | SRR1416889 | GTEX | — | 0.840 |
| 7 | SRR1079591 | GTEX | — | 0.834 |
| 8 | SRR615731 | GTEX | — | 0.833 |
| 9 | BS_5NWDARXG | pilocytic astrocytoma | — | 0.832 |
| 10 | SRR1435753 | GTEX | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.397 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.341 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.334 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.321 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.309 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.309 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.309 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.295 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.273 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.246 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.207 | Inavolisib | — uncovered |
| APOPTOSIS | 0.199 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.193 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.182 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.164 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.133 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.123 | Inavolisib | — uncovered |
| PEROXISOME | 0.119 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.111 | Temsirolimus | — uncovered |